Subarachnoid Hemorrhage, SpontaneousDECIPHER-pmSAHNCT07923084
Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
An observational study of Subarachnoid Hemorrhage, Spontaneous and Subarachnoid Hemorrhage, Aneurysmal, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
Trial summary
Background: Perimesencephalic subarachnoid hemorrhage (pmSAH) is a distinct subtype of traumatic subarachnoid hemorrhage (SAH) characterized by a localized bleeding pattern around the midbrain not resulting from a ruptured aneurysm of a posterior circulation main artery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal, Perimesencephalic Subarachnoid Hemorrhage
- What is being tested?
- Completion of a patient-reported outcome measure (PROM) in the form of a EQ-5D questionnaire
- How many people
- 264 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2026to 31 Mar 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients from participating centers, diagnosed with a perimesencephalic subarachnoid hemorrhage (pmSAH) not resulting from a mechanical trauma or from a ruptured aneurysm of the main arteries of the posterior circulation (V4, Basilar trunk, basilar tip, AICA, PICA, PCA). Taking into account further exclusion criteria (see above), this leaves 2 possible etiologies for pmSAH: 1) basilar artery perforator aneurysms (BAPA); 2) "sine materia" = no vascular lesion could be identified as the source of the pmSAH
Who may be able to join
- Patients aged ≥18 years with a non-traumatic pmSAH or limited additional blood in adjacent cisterns (pmSAH "plus")
- Cross-sectional imaging at baseline (CT or MRI)
- Written informed consent for study participation was obtained.
Who cannot join
- Presence of documented written or verbal refusal
- pmSAH patients with a presumed traumatic source
- Saccular/fusiform aneurysm of the main arteries of the posterior circulation (e.g. V4, AICA, PICA, basilar trunk, basilar tip)
- pmSAH patients with a shunting lesion in the vertebrobasilar territory (i.e. brain AVM, brain/spine AVF)
- pmSAH patients with a cavernous malformation in the posterior fossa
- Basilar artery perforator aneurysm group (BAPA group):
Show all 11Show fewer
- Aneurysm arising from the basilar artery trunk adjacent to a perforating branch but not involving a perforating artery (Satti Type 1)
- Flow-related BAPA (i.e. AVM, AVF)
- Severely impaired renal function defined as KDIGO grade 4 (GFR <30 mL/min/1.73 m2)
- Pregnancy or suspected pregnancy
- Known adverse events to iodinated contrast media
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
Inselspital, University Hospital Bern
Bern, 3010
Tomas Dobrocky, MD, +41 31 632 13 77, tomas.dobrocky@insel.ch
Luca Noti, MD, +41 31 632 70 00, luca.noti@insel.ch
About this study
Official title: Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage - A Prospective Observational Study
Background:
Perimesencephalic subarachnoid hemorrhage (pmSAH) is a distinct subtype of traumatic subarachnoid hemorrhage (SAH) characterized by a localized bleeding pattern around the midbrain not resulting from a ruptured aneurysm of a posterior circulation main artery. Traditionally considered benign with generally good prognosis, pmSAH has been attributed to a presumed venous etiology. However, recent advances in imaging technology have led to the identification of previously occult vascular lesions, most notably basilar artery perforator aneurysms (BAPAs) that may present a potential cause in a subset of patients with pmSAH. Preliminary data from the international PERFAN registry which retrospectively included 148 patients with ruptured BAPAs, challenge the benign perception of pmSAH as a whole. Interestingly, in this biggest case collection so far, patients diagnosed with BAPAs experienced significantly higher rates of complications and worse functional outcomes compared to cases of non-aneurysmal pmSAH (NA-pmSAH). To date, prospective data on prevalence, presentation and outcome of BAPA-associated pmSAH (BAPA-pmSAH) is missing, thus complicating decisions on management of this increasingly diagnosed entity.
Read more
Aims:
The DECIPHER-pmSAH study aims to establish a prospective registry to:
- determine and compare the prevalence of BAPA-pmSAH and non-aneurysmal pmSAH
- compare short-term and mid-term functional outcomes between patients with BAPA-pmSAH and those with non-aneurysmal pmSAH
- evaluate the rate and nature of complications in both these pmSAH subgroups
- enhance the understanding of radiological features associated with pmSAH, with the aim of distinguishing between BAPA-pmSAH and non-aneurysmal pmSAH
- characterize observed treatment strategies and their outcomes, comparing conservative and active management approaches
Design:
The DECIPHER-pmSAH is a prospective, multicenter, observational study. For an adequately powered study, we are aiming at enrollment of at least 264 patients over the course of three years, starting on January 1st, 2026. For recruiting participating sites, we are aiming to build upon the previously established collaboration with multiple international centers contributing to the PERFAN registry, in which cases of perforator aneurysms were retrospectively collected.
Methods:
This study will include cases of atraumatic pmSAH where no aneurysm of main arteries of the posterior circulation was detected. Predefined diagnostic workup criteria must be met for patient enrollment, including cross-sectional imaging (CT or MRI) at baseline, whenever possible and clinically justified at least one digital subtraction angiography (DSA) with high-resolution three-dimensional rotational angiography (3D-RA) and collection of clinical data at index presentation, hospital discharge and 90 days follow-up. Anonymized imaging data will be centrally analyzed by trained neuroradiologists, blinded to clinical data in a core lab at the Inselspital, Bern. The primary endpoint to be examined is the prevalence of ruptured BAPA and non-aneurysmal hemorrhage in cases of pmSAH. Secondary and tertiary endpoints include clinical outcomes at 90 days after index presentations and specific radiological findings respectively.
- Conditions
- Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal, Perimesencephalic Subarachnoid Hemorrhage, Basilar Artery Perforator Aneurysm
- Being tested
- Completion of a patient-reported outcome measure (PROM) in the form of a EQ-5D questionnaire
- Keywords
- Perimesencephalic Subarachnoid Hemorrhage, Basilar Artery Perforator Aneurysm, pmSAH, BAPA, Basal Vein of Rosenthal, BVR
- Medical subject headings
- Subarachnoid Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Completion of a patient-reported outcome measure (PROM) in the form of a EQ-5D questionnaireDiagnostic test
The only study-specific intervention is the collection of a patient-reported outcome measure (PROM) in the form of the EQ-5D questionnaire at 3-month follow-up.
| Study group | Role | What they receive |
|---|---|---|
| All patients included in the study | The only study-specific intervention is the collection of a patient-reported outcome measure (PROM) in the form of the EQ-5D questionnaire at 3-month follow-up for all patients. All other analyzed data are collected as part of routine clinical care. Receives: Diagnostic Test: Completion of a patient-reported outcome measure (PROM) in the form of a EQ-5D questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of BAPAs in pmSAH where at least one high-resolution 3D-rotational angiography (3D-RA) of the dominant vertebral artery was performed within 7 days after the index presentation
Measured: Within 7 days after pmSAH diagnosis
Secondary outcomes (9)
Rate of patients with excellent functional outcome (Modified Rankin Scale 0-1) at 3 months
Measured: 3 months after enrollment
Rate of patients with favorable functional outcome (Modified Rankin Scale 0-2) at 3 months
Measured: 3 months after enrollment
Patient-Reported Outcome (EQ-5D-5L questionnaire) at 3 months
Measured: 3 months after enrollment
Modified Rankin Scale (mRS, range 0-6 with higher scores indicating worse functional status) at hospital discharge
Measured: 21 days after enrollment or hospital discharge (if discharged earlier)
National Institutes of Health Stroke Scale (NIHSS, range 0-42 with higher scores indicating greater neurological impairement) at hospital discharge
Measured: 21 days after enrollment or hospital discharge (if discharged earlier)
Rate of rebleeding
Measured: From enrollment to 3-month follow-up
Rate of hydrocephalus requiring EVD or lumbar drain
Measured: From enrollment to 3-month follow-up
Rate of symptomatic vasospasm
Measured: From enrollment to 3-month follow-up
Rate of BAPAs in pmSAH overall (regardless of 3D-RA acquisition)
Measured: From enrollment to 3-month follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study start1 Jan 2026
- Primary completion31 Mar 2029 (estimated)
- Study completion31 Mar 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (14)Papers the sponsor has linked to this study.
- Other trials for Subarachnoid Hemorrhage, SpontaneousStudies of the same condition, open and under way.
- More trials run by Insel Gruppe AG, University Hospital BernThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 264 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07923084
- Sponsor's protocol ID
- CH-2025-01117
- Acronym
- DECIPHER-pmSAH
- Status last verified
- Sep 2026
- First submitted
- 12 Oct 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Lu GD, Zhao LB, Jia ZY, Liu S. Micro-guidewire electrocoagulation for the treatment of intracranial aneurysms that are inaccessible by microcatheterization: a case series and review of the literature. J Neurointerv Surg. 2023 Dec;15(12):1229-1233. doi: 10.1136/jnis-2022-019355. Epub 2022 Oct 25.
PubMed 36283807Elsheikh S, Mohlenbruch M, Seker F, Berlis A, Maurer C, Kocer N, Jamous A, Behme D, Taschner C, Urbach H, Meckel S. Flow Diverter Treatment of Ruptured Basilar Artery Perforator Aneurysms : A Multicenter Experience. Clin Neuroradiol. 2022 Sep;32(3):783-789. doi: 10.1007/s00062-021-01133-y. Epub 2022 Jan 20.
PubMed 35059755Shlobin NA, Cantrell DR, Ansari SA, Hurley MC, Shaibani A, Jahromi BS, Potts MB. Conservative Management and Natural History of Ruptured Basilar Perforator Artery Aneurysms: Two Cases and Literature Review. World Neurosurg. 2020 Jun;138:218-222. doi: 10.1016/j.wneu.2020.03.042. Epub 2020 Mar 16.
PubMed 32194275Rajbhandari S, Serrallach BL, Raabe JM, Piechowiak EI, Goldberg J, Seiffge DJ, Rentzos A, Zhu F, Scarcia L, Narata A, Amans MR, Premat K, Demerath T, Moehlenbruch M, Kumar R, Limbucci N, Piano M, Burel J, Bellanger G, Dorn F, Hennersdorf F, Stracke P, Milonia L, Cirillo L, Wasselius J, Lenthall R, Flynn L, Keston P, Raz E, Barvulsky E, Giubbolini F, Leonard-Lorant I, Smajda S, Klisch J, Kaiser DPO, Rizzuti M, Tanaka M, Kizilkilic O, Booth TC, Linfante I, Leber SL, Hassan F, Dumas V, Forestier G, Li Y, Alexandre A, Padilla-Palomo FJ, Karwacki GM, Saleem N, Abdalkader M, Herial NA, Pulli B, Tran CC, Raabe A, Gralla J, Bervini D, Z'Graggen WJ, Kaesmacher J, Dobrocky T; PERFAN registry (PERforator ANeurysm registry) collaborators. Differentiating aetiologies in perimesencephalic SAH: clinical insights into basilar artery perforator aneurysms. J Neurol Neurosurg Psychiatry. 2026 Jul 14:jnnp-2026-338621. doi: 10.1136/jnnp-2026-338621. Online ahead of print.
PubMed 42448461Kumagawa T, Otani N, Kakei Y, Negishi H, Suma T, Yoshino A. Ruptured Basilar Artery Perforator Aneurysm Definitely Diagnosed with Intraoperative Microsurgical Findings: Case Report and Literature Review. NMC Case Rep J. 2023 Jan 16;10:1-7. doi: 10.2176/jns-nmc.2022-0184. eCollection 2023.
PubMed 36778213Granja MF, Monteiro A, Agnoletto GJ, Jamal S, Sauvageau E, Aghaebrahim A, Hanel R. A systematic review of non-trunk basilar perforator aneurysms: is it worth chasing the small fish? J Neurointerv Surg. 2020 Apr;12(4):412-416. doi: 10.1136/neurintsurg-2019-015311. Epub 2019 Oct 9.
PubMed 31597686Rouchaud A, Lehman VT, Murad MH, Burrows A, Cloft HJ, Lindell EP, Kallmes DF, Brinjikji W. Nonaneurysmal Perimesencephalic Hemorrhage Is Associated with Deep Cerebral Venous Drainage Anomalies: A Systematic Literature Review and Meta-Analysis. AJNR Am J Neuroradiol. 2016 Sep;37(9):1657-63. doi: 10.3174/ajnr.A4806. Epub 2016 May 12.
PubMed 27173362Hou K, Yu J. Current status of perimesencephalic non-aneurysmal subarachnoid hemorrhage. Front Neurol. 2022 Sep 1;13:960702. doi: 10.3389/fneur.2022.960702. eCollection 2022.
PubMed 36119687Rass V, Altmann K, Zamarian L, Lindner A, Kofler M, Gaasch M, Ianosi BA, Putnina L, Kindl P, Delazer M, Schiefecker AJ, Beer R, Pfausler B, Helbok R. Cognitive, Mental Health, Functional, and Quality of Life Outcomes 1 Year After Spontaneous Subarachnoid Hemorrhage: A Prospective Observational Study. Neurocrit Care. 2024 Aug;41(1):70-79. doi: 10.1007/s12028-023-01895-y. Epub 2023 Dec 21.
PubMed 38129710Jung JY, Kim YB, Lee JW, Huh SK, Lee KC. Spontaneous subarachnoid haemorrhage with negative initial angiography: a review of 143 cases. J Clin Neurosci. 2006 Dec;13(10):1011-7. doi: 10.1016/j.jocn.2005.09.007. Epub 2006 Aug 23.
PubMed 16931020Rinkel GJ, Wijdicks EF, Hasan D, Kienstra GE, Franke CL, Hageman LM, Vermeulen M, van Gijn J. Outcome in patients with subarachnoid haemorrhage and negative angiography according to pattern of haemorrhage on computed tomography. Lancet. 1991 Oct 19;338(8773):964-8. doi: 10.1016/0140-6736(91)91836-j.
PubMed 1681340Mensing LA, Vergouwen MDI, Laban KG, Ruigrok YM, Velthuis BK, Algra A, Rinkel GJE. Perimesencephalic Hemorrhage: A Review of Epidemiology, Risk Factors, Presumed Cause, Clinical Course, and Outcome. Stroke. 2018 Jun;49(6):1363-1370. doi: 10.1161/STROKEAHA.117.019843. Epub 2018 Apr 25.
PubMed 29695465Wallace AN, Vyhmeister R, Dines JN, Chatterjee AR, Kansagra AP, Viets R, Whisenant JT, Moran CJ, Cross DT 3rd, Derdeyn CP. Evaluation of an anatomic definition of non-aneurysmal perimesencephalic subarachnhoid hemorrhage. J Neurointerv Surg. 2016 Apr;8(4):378-85. doi: 10.1136/neurintsurg-2015-011680. Epub 2015 Mar 23.
PubMed 25801775Rinkel GJ, Wijdicks EF, Vermeulen M, Ramos LM, Tanghe HL, Hasan D, Meiners LC, van Gijn J. Nonaneurysmal perimesencephalic subarachnoid hemorrhage: CT and MR patterns that differ from aneurysmal rupture. AJNR Am J Neuroradiol. 1991 Sep-Oct;12(5):829-34.
PubMed 1950905
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage - A Prospective Observational Study
- ClinicalTrials.gov ID
- NCT07923084
- Acronym / sponsor ID
- DECIPHER-pmSAH / CH-2025-01117
- Conditions
- Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal, Perimesencephalic Subarachnoid Hemorrhage, Basilar Artery Perforator Aneurysm
- Keywords
- Perimesencephalic Subarachnoid Hemorrhage, Basilar Artery Perforator Aneurysm, pmSAH, BAPA, Basal Vein of Rosenthal, BVR
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 264 participants (estimated)
- Lead sponsor
- Insel Gruppe AG, University Hospital BernUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 31 Mar 2029 (estimated)
- Study completion
- 31 Mar 2029 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
Perimesencephalic subarachnoid hemorrhage (pmSAH) is a distinct subtype of traumatic subarachnoid hemorrhage (SAH) characterized by a localized bleeding pattern around the midbrain not resulting from a ruptured aneurysm of a posterior circulation main artery. Traditionally considered benign with generally good prognosis, pmSAH has been attributed to a presumed venous etiology. However, recent advances in imaging technology have led to the identification of previously occult vascular lesions, most notably basilar artery perforator aneurysms (BAPAs) that may present a potential cause in a subset of patients with pmSAH. Preliminary data from the international PERFAN registry which retrospectively included 148 patients with ruptured BAPAs, challenge the benign perception of pmSAH as a whole. Interestingly, in this biggest case collection so far, patients diagnosed with BAPAs experienced significantly higher rates of complications and worse functional outcomes compared to cases of non-aneurysmal pmSAH (NA-pmSAH). To date, prospective data on prevalence, presentation and outcome of BAPA-associated pmSAH (BAPA-pmSAH) is missing, thus complicating decisions on management of this increasingly diagnosed entity.
Aims:
The DECIPHER-pmSAH study aims to establish a prospective registry to:
- determine and compare the prevalence of BAPA-pmSAH and non-aneurysmal pmSAH
- compare short-term and mid-term functional outcomes between patients with BAPA-pmSAH and those with non-aneurysmal pmSAH
- evaluate the rate and nature of complications in both these pmSAH subgroups
- enhance the understanding of radiological features associated with pmSAH, with the aim of distinguishing between BAPA-pmSAH and non-aneurysmal pmSAH
- characterize observed treatment strategies and their outcomes, comparing conservative and active management approaches
Design:
The DECIPHER-pmSAH is a prospective, multicenter, observational study. For an adequately powered study, we are aiming at enrollment of at least 264 patients over the course of three years, starting on January 1st, 2026. For recruiting participating sites, we are aiming to build upon the previously established collaboration with multiple international centers contributing to the PERFAN registry, in which cases of perforator aneurysms were retrospectively collected.
Methods:
This study will include cases of atraumatic pmSAH where no aneurysm of main arteries of the posterior circulation was detected. Predefined diagnostic workup criteria must be met for patient enrollment, including cross-sectional imaging (CT or MRI) at baseline, whenever possible and clinically justified at least one digital subtraction angiography (DSA) with high-resolution three-dimensional rotational angiography (3D-RA) and collection of clinical data at index presentation, hospital discharge and 90 days follow-up. Anonymized imaging data will be centrally analyzed by trained neuroradiologists, blinded to clinical data in a core lab at the Inselspital, Bern. The primary endpoint to be examined is the prevalence of ruptured BAPA and non-aneurysmal hemorrhage in cases of pmSAH. Secondary and tertiary endpoints include clinical outcomes at 90 days after index presentations and specific radiological findings respectively.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All patients included in the study | – | Diagnostic Test: Completion of a patient-reported outcome measure (PROM) in the form of a EQ-5D questionnaireThe only study-specific intervention is the collection of a patient-reported outcome measure (PROM) in the form of the EQ-5D questionnaire at 3-month follow-up for all patients. All other analyzed data are collected as part of routine clinical care. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients from participating centers, diagnosed with a perimesencephalic subarachnoid hemorrhage (pmSAH) not resulting from a mechanical trauma or from a ruptured aneurysm of the main arteries of the posterior circulation (V4, Basilar trunk, basilar tip, AICA, PICA, PCA). Taking into account further exclusion criteria (see above), this leaves 2 possible etiologies for pmSAH: 1) basilar artery perforator aneurysms (BAPA); 2) "sine materia" = no vascular lesion could be identified as the source of the pmSAH
Key inclusion criteria (3 listed)
- Patients aged ≥18 years with a non-traumatic pmSAH or limited additional blood in adjacent cisterns (pmSAH "plus")
- Cross-sectional imaging at baseline (CT or MRI)
- Written informed consent for study participation was obtained.
Key exclusion criteria (11 listed)
- Presence of documented written or verbal refusal
- pmSAH patients with a presumed traumatic source
- Saccular/fusiform aneurysm of the main arteries of the posterior circulation (e.g. V4, AICA, PICA, basilar trunk, basilar tip)
- pmSAH patients with a shunting lesion in the vertebrobasilar territory (i.e. brain AVM, brain/spine AVF)
- pmSAH patients with a cavernous malformation in the posterior fossa
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Completion of a patient-reported outcome measure (PROM) in the form of a EQ-5D questionnaireThe only study-specific intervention is the collection of a patient-reported outcome measure (PROM) in the form of the EQ-5D questionnaire at 3-month follow-up. | Diagnostic test | All patients included in the study |
Primary outcome
Rate of BAPAs in pmSAH where at least one high-resolution 3D-rotational angiography (3D-RA) of the dominant vertebral artery was performed within 7 days after the index presentation
Time frame: Within 7 days after pmSAH diagnosis
9 secondary outcomes
Rate of patients with excellent functional outcome (Modified Rankin Scale 0-1) at 3 months
Time frame: 3 months after enrollment
Rate of patients with favorable functional outcome (Modified Rankin Scale 0-2) at 3 months
Time frame: 3 months after enrollment
Patient-Reported Outcome (EQ-5D-5L questionnaire) at 3 months
Time frame: 3 months after enrollment
Modified Rankin Scale (mRS, range 0-6 with higher scores indicating worse functional status) at hospital discharge
Time frame: 21 days after enrollment or hospital discharge (if discharged earlier)
National Institutes of Health Stroke Scale (NIHSS, range 0-42 with higher scores indicating greater neurological impairement) at hospital discharge
Time frame: 21 days after enrollment or hospital discharge (if discharged earlier)
Rate of rebleeding
Time frame: From enrollment to 3-month follow-up
Rate of hydrocephalus requiring EVD or lumbar drain
Time frame: From enrollment to 3-month follow-up
Rate of symptomatic vasospasm
Time frame: From enrollment to 3-month follow-up
Rate of BAPAs in pmSAH overall (regardless of 3D-RA acquisition)
Time frame: From enrollment to 3-month follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Background: PubMed 36283807Lu GD, Zhao LB, Jia ZY, Liu S. Micro-guidewire electrocoagulation for the treatment of intracranial aneurysms that are inaccessible by microcatheterization: a case series and review of the literature. J Neurointerv Surg. 2023 Dec;15(12):1229-1233. doi: 10.1136/jnis-2022-019355. Epub 2022 Oct 25.
- Background: PubMed 35059755Elsheikh S, Mohlenbruch M, Seker F, Berlis A, Maurer C, Kocer N, Jamous A, Behme D, Taschner C, Urbach H, Meckel S. Flow Diverter Treatment of Ruptured Basilar Artery Perforator Aneurysms : A Multicenter Experience. Clin Neuroradiol. 2022 Sep;32(3):783-789. doi: 10.1007/s00062-021-01133-y. Epub 2022 Jan 20.
- Background: PubMed 32194275Shlobin NA, Cantrell DR, Ansari SA, Hurley MC, Shaibani A, Jahromi BS, Potts MB. Conservative Management and Natural History of Ruptured Basilar Perforator Artery Aneurysms: Two Cases and Literature Review. World Neurosurg. 2020 Jun;138:218-222. doi: 10.1016/j.wneu.2020.03.042. Epub 2020 Mar 16.
- Background: PubMed 42448461Rajbhandari S, Serrallach BL, Raabe JM, Piechowiak EI, Goldberg J, Seiffge DJ, Rentzos A, Zhu F, Scarcia L, Narata A, Amans MR, Premat K, Demerath T, Moehlenbruch M, Kumar R, Limbucci N, Piano M, Burel J, Bellanger G, Dorn F, Hennersdorf F, Stracke P, Milonia L, Cirillo L, Wasselius J, Lenthall R, Flynn L, Keston P, Raz E, Barvulsky E, Giubbolini F, Leonard-Lorant I, Smajda S, Klisch J, Kaiser DPO, Rizzuti M, Tanaka M, Kizilkilic O, Booth TC, Linfante I, Leber SL, Hassan F, Dumas V, Forestier G, Li Y, Alexandre A, Padilla-Palomo FJ, Karwacki GM, Saleem N, Abdalkader M, Herial NA, Pulli B, Tran CC, Raabe A, Gralla J, Bervini D, Z'Graggen WJ, Kaesmacher J, Dobrocky T; PERFAN registry (PERforator ANeurysm registry) collaborators. Differentiating aetiologies in perimesencephalic SAH: clinical insights into basilar artery perforator aneurysms. J Neurol Neurosurg Psychiatry. 2026 Jul 14:jnnp-2026-338621. doi: 10.1136/jnnp-2026-338621. Online ahead of print.
- Background: PubMed 36778213Kumagawa T, Otani N, Kakei Y, Negishi H, Suma T, Yoshino A. Ruptured Basilar Artery Perforator Aneurysm Definitely Diagnosed with Intraoperative Microsurgical Findings: Case Report and Literature Review. NMC Case Rep J. 2023 Jan 16;10:1-7. doi: 10.2176/jns-nmc.2022-0184. eCollection 2023.
- Background: PubMed 31597686Granja MF, Monteiro A, Agnoletto GJ, Jamal S, Sauvageau E, Aghaebrahim A, Hanel R. A systematic review of non-trunk basilar perforator aneurysms: is it worth chasing the small fish? J Neurointerv Surg. 2020 Apr;12(4):412-416. doi: 10.1136/neurintsurg-2019-015311. Epub 2019 Oct 9.
- Background: PubMed 27173362Rouchaud A, Lehman VT, Murad MH, Burrows A, Cloft HJ, Lindell EP, Kallmes DF, Brinjikji W. Nonaneurysmal Perimesencephalic Hemorrhage Is Associated with Deep Cerebral Venous Drainage Anomalies: A Systematic Literature Review and Meta-Analysis. AJNR Am J Neuroradiol. 2016 Sep;37(9):1657-63. doi: 10.3174/ajnr.A4806. Epub 2016 May 12.
- Background: PubMed 36119687Hou K, Yu J. Current status of perimesencephalic non-aneurysmal subarachnoid hemorrhage. Front Neurol. 2022 Sep 1;13:960702. doi: 10.3389/fneur.2022.960702. eCollection 2022.
- Background: PubMed 38129710Rass V, Altmann K, Zamarian L, Lindner A, Kofler M, Gaasch M, Ianosi BA, Putnina L, Kindl P, Delazer M, Schiefecker AJ, Beer R, Pfausler B, Helbok R. Cognitive, Mental Health, Functional, and Quality of Life Outcomes 1 Year After Spontaneous Subarachnoid Hemorrhage: A Prospective Observational Study. Neurocrit Care. 2024 Aug;41(1):70-79. doi: 10.1007/s12028-023-01895-y. Epub 2023 Dec 21.
- Background: PubMed 16931020Jung JY, Kim YB, Lee JW, Huh SK, Lee KC. Spontaneous subarachnoid haemorrhage with negative initial angiography: a review of 143 cases. J Clin Neurosci. 2006 Dec;13(10):1011-7. doi: 10.1016/j.jocn.2005.09.007. Epub 2006 Aug 23.
- Background: PubMed 1681340Rinkel GJ, Wijdicks EF, Hasan D, Kienstra GE, Franke CL, Hageman LM, Vermeulen M, van Gijn J. Outcome in patients with subarachnoid haemorrhage and negative angiography according to pattern of haemorrhage on computed tomography. Lancet. 1991 Oct 19;338(8773):964-8. doi: 10.1016/0140-6736(91)91836-j.
- Background: PubMed 29695465Mensing LA, Vergouwen MDI, Laban KG, Ruigrok YM, Velthuis BK, Algra A, Rinkel GJE. Perimesencephalic Hemorrhage: A Review of Epidemiology, Risk Factors, Presumed Cause, Clinical Course, and Outcome. Stroke. 2018 Jun;49(6):1363-1370. doi: 10.1161/STROKEAHA.117.019843. Epub 2018 Apr 25.
- Individual participant dataSharing planned: Yes
Related trials for Subarachnoid Hemorrhage, Spontaneous
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
RecruitingPhase 2
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal, Headache
Active, not recruiting
Auricular VNS Following Subarachnoid Hemorrhage
Subarachnoid Hemorrhage
RecruitingPhase 2
Evaluation of the Safety and Efficacy of Parecoxib in Patients With Subarachnoid Hemorrhage
Neurological Complication
RecruitingPhase 2
BLOCK-SAH - PPF-Block for Post-SAH Headache
Subarachnoid Hemorrhage, Aneurysmal, Headache
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Subarachnoid Hemorrhage, Spontaneous and Subarachnoid Hemorrhage, Aneurysmal, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tomas Dobrocky, MD (+41 31 632 13 77, tomas.dobrocky@insel.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of BAPAs in pmSAH where at least one high-resolution 3D-rotational angiography (3D-RA) of the dominant vertebral artery was performed within 7 days after the index presentation (time frame: Within 7 days after pmSAH diagnosis). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07923084, which also lists 14 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.